May 19, 2014
Phase II STOP-HF Trial Shows Excellent Safety Profile, Supports Efficacy for Juventas JVS-100 as Delivered by BioCardia® Helix™ Transendocardial Delivery System
May 7, 2014
RECARDIO Clinical Trial Doses First Patient
March 17, 2014
BioCardia® Receives CE Mark for Morph AccessPro™ Steerable Introducer
November 18, 2013
Phase II TAC-HFT Trial Shows Excellent Safety Profile, Suggests Efficacy, for Transendocardial Delivery of Two Types of Autologous Cells for Ischemic Heart Failure
BioCardia is developing proprietary comprehensive biotherapeutic solutions for cardiovascular disease in its CardiAMP™ and CardiALLO™ therapies. Clinical results supporting both therapeutic programs are compelling and build upon the most rigorous data in the field to date with intramyocardial delivery of marrow-derived cells.
These programs are enabled by the Company's Helix™ transendocardial delivery systems and Morph® vascular access products, which are partnered to enable other promising biotherapeutic programs.